유전체 편집 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 제공 방법별, 용도별, 모드별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Genome Editing Market Summary

The global genome editing market size was estimated at USD 11.37 billion in 2025 and is projected to reach USD 39.81 billion by 2033, growing at a CAGR of 17.03% from 2026 to 2033. This growth can be attributed to the success in preclinical models driving the demand for genome editing therapeutics, rising competition among market participants for business development, technological advancements in gene editing technologies, and increasing adoption in agricultural biotechnology.

The COVID-19 pandemic had a significant impact on the market, causing disruptions in several aspects of the market including clinical trial disruptions, supply chain challenges, and stringent regulations. Manufacturing & supply chains were also affected by lockdown measures, travel restrictions, and reduced workforce, leading to delays in the production & distribution of gene therapy products. Despite these challenges, companies in the genome editing industry have adjusted to the new normal by implementing adaptive measures and are expected to recover from the impact of COVID-19. The pandemic accelerated R&D activities in gene alteration technologies, specifically in response to the urgent need for effective treatments and vaccines for COVID-19. For example, researchers at Nanyang Technological University developed the VaNGuard (Variant Nucleotide Guard) diagnostic test in March 2021, which has the capability to detect SARS-CoV-2 strains with mutations. This advancement is anticipated to leverage the utilization of CRISPR genome editing technology.

The rapid evolution of CRISPR-based tools has significantly led to the expansion of the genome editing industry. The emergence of innovative genome editing tools, which allow easier manipulation of genomic DNA, has brought in a new phase in therapeutic development and disease detection, which derives the growth in rare disease genome editing industry. Consequently, service providers now have a profitable opportunity to tap previously unexplored areas in this field. Moreover, increasing government funding, growing production of genetically modified crops, and a rising number of genomics projects are expected to drive market growth.

Many companies are entering into licensing agreements with technology developers to strengthen their market presence, while key players are engaged in strategic initiatives like acquisitions and partnerships to expand their global presence. For instance, in February 2024, Precision BioSciences granted Caribou Biosciences a non-exclusive, global license to use its patented technology for targeted insertion of exogenous antigen binding receptors into the TRAC gene locus of human T cells. This agreement includes upfront payment, royalties on product sales, and potential milestone payments.

Gene editing technology CRISPR is projected to be the burgeoning technology in biotechnology. CRISPR harnesses the bacterial immune system to either knock genes out or insert new genes. Due to their time-consuming, ineffective, and labor-intensive nature, traditional genome editing methods are only partially capable of keeping pace with the rapidly evolving genome modification era. In addition, technology also provides transformative results in various fields, such as plant, animal, & cell line genetic engineering and drug development & monitoring, which results in growth of the market. Technology has the potential to investigate different gene combinations, control gene expression, and find the role of individual DNA bases.

Advancements in genomics and related technologies have significantly impacted crop genetics. Genomes and transcriptomes can now be sequenced for many crops. Major benefits of gene manipulation tools in agricultural sectors include the development of Genetically Modified (GM) plants/crops with various advanced features, such as increased crop productivity. They also help conserve biodiversity, reduce agricultural eco-footprint, mitigate climate change, and aid in alleviating poverty and hunger.

Global Genome Editing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global genome editing market report based on technology, delivery method, application, mode, end use, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganucleases
• Others
• Delivery Method Outlook (Revenue, USD Million, 2021 - 2033)
• Ex-vivo
• In-vivo
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Genetic Engineering
  • Cell line engineering
  • Animal genetic engineering
  • Plant genetic engineering
  • Others
• Clinical Applications
  • Diagnostics Development
  • Therapy Development
• Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Contract
• In-house
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. Delivery Method Segment
  • 1.2.3. Application Segment
  • 1.2.4. Mode Segment
  • 1.2.5. End Use Segment
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Genome Editing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Success in pre-clinical models drives demand for genome editing therapeutics
    • 3.2.1.2. Rising competition amongst market participants for business development
    • 3.2.1.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
    • 3.2.1.4. Increasing demand for synthetic genes and genetically modified organisms
    • 3.2.1.5. Technological advancements in gene editing technologies
    • 3.2.1.6. Rising adoption in agricultural biotechnology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges concerning clinical translation
    • 3.2.2.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
    • 3.2.2.3. Off-target effects of CRISPR technology
• 3.3. Genome Editing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Genome Editing Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Genome Editing Market Technology Movement Analysis
• 4.3. Global Genome Editing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 4.4. (CRISPR)/Cas9
  • 4.4.1. (CRISPR)/Cas9 market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. TALENs/MegaTALs
  • 4.5.1. TALENs/MegaTALs market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. ZFN
  • 4.6.1. ZFN market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Meganuclease
  • 4.7.1. Meganuclease market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Genome Editing Market: Delivery Method Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Genome Editing Market Delivery Method Movement Analysis
• 5.3. Global Genome Editing Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
• 5.4. Ex Vivo
  • 5.4.1. Ex vivo market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. In-Vivo
  • 5.5.1. In-vivo market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Genome Editing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Genome Editing Market Application Movement Analysis
• 6.3. Global Genome Editing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Genetic Engineering
  • 6.4.1. Genetic Engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Cell Line Engineering
    • 6.4.2.1. Cell line engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Animal Genetic Engineering
    • 6.4.3.1. Animal genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Plant Genetic Engineering
    • 6.4.4.1. Plant genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Others
    • 6.4.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Clinical Applications
  • 6.5.1. Clinical applications market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. Diagnostics Development
    • 6.5.2.1. Diagnostics development market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. Therapy Development
    • 6.5.3.1. Therapy development market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Genome Editing Market: Mode Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Genome Editing Market Mode Movement Analysis
• 7.3. Global Genome Editing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
• 7.4. Contract
  • 7.4.1. Contract market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. In-house
  • 7.5.1. In-house market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Genome Editing Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Genome Editing Market End-Use Movement Analysis
• 8.3. Global Genome Editing Market Size & Trend Analysis, by End-Use, 2021 to 2033 (USD Million)
• 8.4. Biotechnology and pharmaceutical companies
  • 8.4.1. Biotechnology and pharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Academic and government research institutes
  • 8.5.1. Academic and government research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Contract research organizations
  • 8.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Genome Editing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. U.S.
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Target disease prevalence
    • 9.4.1.4. Competitive scenario
    • 9.4.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Canada
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. Mexico
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. UK
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Target disease prevalence
    • 9.5.1.4. Competitive scenario
    • 9.5.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. Germany
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. France
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. Italy
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. Spain
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Target disease prevalence
    • 9.5.5.4. Competitive scenario
    • 9.5.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Norway
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Target disease prevalence
    • 9.5.6.4. Competitive scenario
    • 9.5.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.7. Sweden
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Target disease prevalence
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Competitive scenario
    • 9.5.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.8. Denmark
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework
    • 9.5.8.3. Target disease prevalence
    • 9.5.8.4. Competitive scenario
    • 9.5.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Japan
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Target disease prevalence
    • 9.6.1.4. Competitive scenario
    • 9.6.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. China
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Target disease prevalence
    • 9.6.2.4. Competitive scenario
    • 9.6.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.3. India
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.4. Australia
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Target disease prevalence
    • 9.6.4.4. Competitive scenario
    • 9.6.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.5. South Korea
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Target disease prevalence
    • 9.6.5.4. Competitive scenario
    • 9.6.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.6. Thailand
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Target disease prevalence
    • 9.6.6.3. Regulatory framework
    • 9.6.6.4. Competitive scenario
    • 9.6.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Brazil
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Target disease prevalence
    • 9.7.1.4. Competitive scenario
    • 9.7.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Argentina
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Target disease prevalence
    • 9.7.2.4. Competitive scenario
    • 9.7.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.8. MEA
  • 9.8.1. South Africa
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Target disease prevalence
    • 9.8.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.2. Saudi Arabia
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Target disease prevalence
    • 9.8.2.4. Competitive scenario
    • 9.8.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.3. UAE
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework
    • 9.8.3.3. Target disease prevalence
    • 9.8.3.4. Competitive scenario
    • 9.8.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.4. Kuwait
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Regulatory framework
    • 9.8.4.3. Target disease prevalence
    • 9.8.4.4. Competitive scenario
    • 9.8.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2025
• 10.4. Company Profiles/Listing
  • 10.4.1. Merck KGaA
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Takara Bio Inc.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Revvity, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Danaher Corporation
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. GenScript
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. New England Biolabs
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Charles River Laboratories
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Eurofins Scientific
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Lonza
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Thermo Fisher Scientific, Inc.
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives